Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec Compensation
confidence 95%
filed 2026-09-29
Item 5.02
The filing discloses extension employment agreements for two named executives—Dr. Anil Diwan (President) and Meeta Vyas (CFO)—that modify their compensatory arrangements. Dr. Diwan's extension includes a base salary of $400,000, a $2 million term life insurance policy, and a grant of 10,204 shares of Series A Preferred Stock with quarterly vesting through June 30, 2027. Ms. Vyas's extension continues her monthly compensation of $10,800 and adds a new health insurance reimbursement benefit up to $2,500 per month. These are material modifications to executive compensation arrangements disclosed under Item 5.02(e).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-29
Item 5.02
Dean Liollio was appointed as Executive Vice President and Chief Operating Officer of Plains GP Holdings LP, effective October 2, 2026, replacing Chris Chandler who resigned. The appointment includes a base salary of $625,000, a 150% bonus target, and a 150,000 phantom units long-term incentive plan grant.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-09-29
Item 8.01
CION announced repayment in full of $114.8 million in Israel Series A Notes and approximately $200 million under its JPMorgan Credit Facility, along with closing of a strategic joint venture transaction involving $125 million in senior secured notes and $59.7 million in membership interests. These transactions materially reduce the company's leverage (pro-forma net leverage to 1.35x) and represent significant capital structure and financing activity. While the debt repayment could be classified as debt_issuance (the joint venture issuance), the core disclosure centers on debt reduction and a strategic financing restructuring rather than creation of new direct obligations to CION itself, making financial_other the most appropriate classification for this multi-faceted capital transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
Item 5.07
FedEx held its annual stockholder meeting on September 28, 2026, with voting results on six proposals: election of eleven directors, advisory approval of named executive officer compensation, ratification of Ernst & Young LLP as independent auditor, and three stockholder proposals (all rejected).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-09-29
Item 8.01
FedEx's Board approved updated compensation arrangements for outside directors in September 2026, increasing the annual equity grant by $20,000 from $195,000 to $215,000.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-29
Item 5.07
TechPrecision Corporation held its Annual Meeting on September 29, 2026, with shareholders voting on four proposals: election of five directors, ratification of CBIZ CPAs P.C. as independent auditor, advisory approval of named executive officer compensation, and approval of an amended and restated 2016 Equity Incentive Plan increasing authorized shares by 750,000 and extending the plan's expiration to 2036.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-09-29
Item 1.01
Spark I Acquisition Corp entered into a Second Extension Note with its Sponsor to extend the deadline for completing its initial business combination with ZincFive, Inc. from September 29, 2026 to March 29, 2027, supported by a $0.10 per-share contribution to the trust account.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
Item 5.07
Shareholders approved an Extension Amendment at an extraordinary general meeting on September 25, 2026, with 7,074,069 votes in favor and 57,456 against, extending the business combination deadline to March 29, 2027.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-29
Item 1.01
Cboe Global Markets entered into a Master License Agreement with S&P Dow Jones Indices extending and expanding exclusive licensing rights for S&P 500 index options through 2051, superseding the 1994 restated license and including updated fee structures effective 2027. This 25-year extension represents a material strategic commitment affecting Cboe's core business operations and revenue model for its flagship SPX options product.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-29
Item 8.01
Oncolytics disclosed publication of preclinical data in the Proceedings of the National Academy of Sciences demonstrating pelareorep's ability to convert immunologically inactive liver tumors to active, potentially susceptible to immunotherapy. This is a material operational/scientific milestone for a clinical-stage biotech company, supporting the therapeutic narrative and business development conversations around pelareorep as a backbone immunotherapy. While not a specific named event type (not earnings, M&A, litigation, etc.), it is clearly material to investors assessing the company's pipeline and competitive positioning, and fits best within operational_other as a significant research/development milestone.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-09-29
Item 2.01
Global Business Travel Group, Inc. completed a $6.3 billion all-cash acquisition by Long Lake Management at $9.50 per share (65.1% premium), with the company delisting from NYSE and transitioning to private ownership. The transaction was previously announced on May 4, 2026, and approved by stockholders on August 3, 2026. Concurrent with closing, the company entered into a $1.75 billion credit facility and terminated its prior credit agreement.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-29
Item 7.01
T. Rowe Price OHA Select Private Credit Fund declared regular distributions of $0.20 per share for all classes of common shares, with a record date of September 30, 2026 and payment date of October 30, 2026.
View raw filing on EDGAR →
8-K
Financial Other
confidence 65%
filed 2026-09-29
Item 8.01
The Fund disclosed its NAV per share of $26.07 as of August 31, 2026, aggregate NAV of $1,619.6 million, investment portfolio fair value, debt outstanding, debt-to-equity ratio, and the status of an ongoing $2.5 billion public offering of shares with $1.6+ billion raised to date.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-29
Item 2.02
CarMax issued a press release on September 29, 2026, announcing second quarter fiscal 2027 results, including total net revenues of $7.9 billion (up 19.5%), net earnings per diluted share of $1.16 (up 81.3%), and detailed operational metrics. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, with material financial results that would affect investor assessment of the company's performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-09-29
Item 1.01
BeyondSpring entered into a Share Purchase and Collaboration Agreement on September 28, 2026, to sell its entire equity interest in BeyondSpring Ltd. (which indirectly holds majority interest in its Chinese subsidiary Bulin) to Biolin Investment Limited. The buyer will provide non-cash consideration through funding of the China portion of the Phase 3 DUBLIN-4 trial, substantially reducing BeyondSpring's cash requirements while advancing a critical clinical milestone.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-29
EX-99.1
The exhibit is a Material Change Report (Form 51-102F3) announcing the appointment of Melanie Pump to Optimi Health's Board of Directors on September 29, 2026. While the filing also discloses Leah Hodges' resignation as Corporate Secretary and Dane Stevens' appointment to that role, the principal disclosed action is the board appointment of a new director with significant financial and governance experience. This is a material governance event affecting the composition of the board.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-29
Item 7.01
OMNIQ announced two municipal agreements in Pennsylvania for deployment of its Q Shield Safe City platform, representing the company's first deployments in that state. The agreements establish a transaction-based recurring revenue model tied to citation processing fees and involve 18 cameras across nine intersections. This is a material operational and strategic business development—a new market entry with repeatable revenue opportunity—that does not fit the specific categories of M&A, earnings release, or other named event types. The disclosure is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's growth prospects and revenue diversification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-29
EX-99.1
This press release discloses exploration results and drilling updates across Equinox Gold's Canadian mining operations (Musselwhite, Valentine, and Greenstone), highlighting mineral resource growth potential, mine-life extension opportunities, and a new discovery (Minotaur). While the company frames this as supporting "organic growth strategy" and future mineral reserve replacement, the disclosure is fundamentally an operational/exploration update rather than a discrete event like M&A, impairment, or executive change. The material nature reflects that exploration success directly impacts future production capacity and asset value, affecting investor assessment of long-term growth prospects.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-29
Item 8.01
John M. Pereira resigned from the boards of directors of Beacon Financial Corporation and its subsidiary Beacon Bank & Trust, effective September 30, 2026. This is a clear director departure disclosed under Item 8.01, and director resignations are material events affecting the composition of the company's governance structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-29
EX-99.1
Kenon Holdings announces the appointment of Duncan J. Bullock to its Board of Directors as a non-executive director, effective September 29, 2026. This is a clear executive/governance appointment that would affect a reasonable investor's assessment of board composition and oversight. The disclosure explicitly names the appointee, his role, and his relevant experience in the energy sector.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-09-29
Item 1.01
Silexion entered into an inducement letter agreement on September 28, 2026, whereby warrant holders exercised existing Series E warrants at a reduced exercise price ($0.2603 vs. $0.65) in exchange for new Series F and G warrants to purchase 6,433,856 additional ordinary shares. The transaction, structured as a private placement under Section 4(a)(2), generates approximately $0.84 million in gross proceeds while creating substantial new dilution through the issuance of 6.4+ million warrant shares.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-29
EX-99.1
EShallGo Inc. is holding an extraordinary general meeting of shareholders on October 10, 2026, to approve three material governance matters: a 5-for-1 share consolidation to comply with Nasdaq's minimum bid price requirement, adoption of amended and restated memorandum and articles of association, and migration of the company's domicile from the Cayman Islands to the British Virgin Islands.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-29
EX-99.1
This press release announces the completion of development of Diamond Ultra V2, a next-generation video and AI platform for defense applications. The disclosure describes a significant product milestone—completion of a new system-level platform designed to expand Maris-Tech's capabilities across key markets (situational awareness, terrain dominance, counter-UAS, airborne applications). While this is a product development milestone rather than a discrete operational restructuring or material contract, it represents a material strategic advancement in the company's product portfolio that would affect a reasonable investor's assessment of the company's competitive position and growth prospects in its core defense markets.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-09-29
The filing announces SMFG's decision to execute a share exchange agreement whereby SMBC Nikko Securities Inc. will become a wholly owned subsidiary of a newly established intermediate holding company (SMBC Nikko Securities Holdings Inc.) effective October 1, 2026. This is a material change of control and restructuring of subsidiary relationships within the SMFG group, involving a statutory share exchange that alters the corporate structure and governance of a major subsidiary engaged in financial instruments business with JPY 21.7 billion in total assets.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 85%
filed 2026-09-29
This 6-K furnishes a Taiwan Stock Exchange (TWSE) disclosure of financial information triggered by reaching a trading-information disclosure threshold. The exhibit presents unaudited monthly revenue (August 2026: NT$2,786M, +33.3% YoY), reviewed quarterly results (2026Q2: NT$7,383M revenue, +28.7% YoY; NT$892M profit attributable to owners, +267.4% YoY), and audited/reviewed 4-quarter accumulation data. While framed as a threshold-triggered regulatory filing rather than a voluntary earnings press release, it discloses interim financial results and is material to investors assessing the registrant's performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-29
Item 8.01
Aldeyra disclosed its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs to appeal a Complete Response Letter denying approval of reproxalap for dry eye disease, along with an extension of projected operational cash runway into 2029. This represents a material strategic and regulatory development as the FDRR is a significant pathway to challenge the FDA's rejection of the company's lead product candidate.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-29
Item 1.01
Sherwin-Williams entered into a new $750 million senior unsecured term loan credit agreement on September 24, 2026, replacing an existing 364-day facility, and its Luxembourg subsidiary simultaneously entered into a new €100 million term loan agreement with ING Bank, with the parent company providing a guaranty. These refinancing arrangements constitute material creation of new direct financial obligations affecting the registrant's capital structure and liquidity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-29
Item 8.01
Invivyd announced positive Phase 3 topline results from the LIBERTY study demonstrating that VYD2311 met all primary and secondary endpoints with superior safety and tolerability compared to mRNA-based COVID-19 vaccine, and announced plans to submit a Biologics License Application (BLA) to the FDA via the Accelerated Approval Program. This is a material clinical milestone and regulatory development for an investigational drug candidate, but does not fit neatly into the specific event categories (not earnings, not M&A, not a restatement, not a covenant breach, etc.). The disclosure centers on positive clinical trial results and regulatory pathway advancement, which are operational/strategic milestones for a biopharmaceutical company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-09-29
Item 1.01
SoundThinking entered into a definitive Agreement and Plan of Merger with Transom Capital Group on September 28, 2026, providing for a tender offer at $8.00 per share in cash plus contingent value rights worth up to $3.00 per share, representing a 46% premium to the closing price and an implied enterprise value of approximately $114–159 million. The transaction is unanimously approved by the Board, with shareholders owning ~33% already committed to tender, and is expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-09-29
Item 5.02
The Compensation Committee approved compensatory arrangements for named executives Ralph A. Clark (CEO) and Alan R. Stewart (CFO) in connection with the Merger, including transaction bonuses ($525,000 and $200,000 respectively) and amended severance benefits comprising 12-month base salary, COBRA reimbursement, pro-rated bonus, and equity acceleration.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-09-29
Item 8.01
The board of directors approved a plan to issue contingent value rights (CVRs) stapled to common shares, entitling shareholders to 25% of net proceeds (capped at $50 million) from monetization of Atossa's first qualifying rare pediatric disease priority review voucher. This is a governance decision affecting shareholder rights and capital structure, though it also has financial implications. The event is material because it creates a new contractual right for shareholders tied to potential future value, but it does not fit neatly into specific categories like exec_compensation or dividend_distribution—it is a novel shareholder-value mechanism approved by the board.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-29
Item 1.01
TransDigm completed the issuance of $3,000 million of 6.75% Senior Secured Notes maturing in 2035 on September 28, 2026. The company intends to use proceeds to repurchase existing 2028 notes and for general corporate purposes, representing a significant refinancing and capital structure event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-29
Item 8.01
NewAmsterdam announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in preclinical Alzheimer's disease. This represents a material clinical development milestone—expansion of the company's pipeline into a new indication (neurodegenerative disease) and advancement of a key product candidate. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development progress and market opportunity.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-29
Item 8.01
PRA Group announced its intent to offer $400.0 million aggregate principal amount of senior notes due 2033 in a private transaction. This is a creation of a new direct financial obligation through debt issuance. The company intends to use net proceeds to repay approximately $400.0 million of outstanding borrowings under its North American revolving credit facility, representing a material refinancing activity that would affect investor assessment of the company's capital structure and liquidity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-29
Item 5.02
The filing discloses the appointment of Hubert Crouch as Chief Executive Officer, President, and Board member of Apollo Realty Income Solutions, effective September 30, 2026. While the section also mentions the resignation of prior CEO Jess Lipsey, the principal disclosed action centers on the appointment of a new CEO with detailed background information, making exec_appointment the most salient event. This is material as it represents a change in the company's top leadership.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-29
Item 7.01
SmartStop announced a series of strategic initiatives totaling ~$140 million including: (1) a joint venture investment in Strategic Storage Canada positioning it as Canada's third-largest operator; (2) acquisition of two wholly-owned U.S. properties for ~$37 million; (3) a programmatic investment partnership with a Class A developer; and (4) a strategic asset disposition program targeting $75–125 million in noncore property sales. The company also raised full-year 2026 same-store and FFO guidance. This is primarily an operational/strategic business announcement—expansion of geographic footprint, clustering strategy, and capital redeployment—rather than a discrete financial event (debt issuance, M&A completion, or earnings release). The guidance raise is secondary to the operational announcements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-29
Item 3.02
The Fund sold approximately $79.9 million in unregistered limited partnership units (Class R-S and Class R-I Units) on September 1, 2026, as part of a continuous private offering exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-09-29
Item 2.02
Fidelity Core Real Estate Fund disclosed its financial results and performance metrics as of August 31, 2026, including NAV per share of $11.57, annualized net total return of 8.85% since inception, and distribution rates of 4.74%, along with portfolio composition and monthly returns for 2023–2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-29
Item 3.02
The fund issued 17,386.585 Class I common shares for $350,000 as part of a continuous private offering, relying on Section 4(a)(2) and Regulation D/S exemptions.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-29
Item 8.01
The fund declared a regular monthly distribution of $0.15 per share for Class I Shares, payable on or about October 8, 2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-29
Item 7.01
The filing discloses a declared distribution of $0.0434 per share for Class I Common Shares of Fidelity Core Real Estate Fund, payable to shareholders of record on September 30, 2026, with payment on or about October 22, 2026. This is a routine periodic dividend distribution for a real estate fund, which is material to shareholders as it represents a return of capital and affects investment returns.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-29
Item 8.01
The filing discloses a declaration of a quarterly cash dividend of $0.12 per common share, payable on October 26, 2026, to shareholders of record as of October 13, 2026. This is a routine but material dividend distribution event. The press release emphasizes Helios's 29-year history of consecutive quarterly dividends (119th consecutive), which is a significant capital allocation decision affecting shareholders.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-09-29
Item 1.01
The Company entered into a Fourth Amendment to its Loan and Security Agreement that increases available loan commitments from $125 million to $175 million, adds MUFG Bank, Ltd. as a new lender, and expands eligible collateral to include middle market loans, materially increasing the Company's direct financial obligations and borrowing capacity.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-29
Item 8.01
The Board of Directors has authorized a distribution to stockholders of record as of September 30, 2026, with specific per-share amounts for each class of common stock (ranging from $0.0878 to $0.1042 net per share depending on class). The distributions are payable on or about October 5, 2026, and may be paid in cash or reinvested through the company's distribution reinvestment plan. This is a clear dividend/distribution declaration material to investors in a real estate income trust.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-09-29
The 6-K discloses the closing of a warrant exercise window resulting in the issuance of 210,812 ordinary shares at an average price of approximately USD $123.36 per share, increasing share capital by nominal DKK 210,812. This constitutes a dilutive equity issuance that would materially affect shareholder ownership and is reportable under Item 3.02 equivalent disclosure requirements for foreign private issuers.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-29
Item 8.01
The filing discloses authorization by the board of directors of a cash distribution to stockholders of $0.1356 per share, payable on or about October 7, 2026, to shareholders of record as of September 30, 2026. This is a routine but material dividend distribution typical of REITs, which are required to distribute substantially all taxable income to shareholders. The disclosure explicitly states the per-share amount, record date, and payment date.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-29
Item 5.02
The filing discloses the appointment of John B. Harlow, Jr. as President and Chief Operating Officer of Larimar Therapeutics, effective September 29, 2026. While the disclosure includes compensatory details (base salary of $560,000, signing bonus, equity grants of 800,000 options and 50,000 RSUs), the principal disclosed action is the appointment of a named executive officer to a senior leadership role. This is material to investors as it represents a significant change in the Company's executive leadership structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-09-29
Item 1.01
The Company amended a revolving line of credit facility with Vivasor, increasing the Maximum Credit Amount from $20 million to $30 million. This constitutes a material amendment to an existing direct financial obligation (a credit facility), which falls under debt_issuance. The $10 million increase is material, and the transaction was approved by the Board and Audit Committee. The related-party nature (CEO serves as Vivasor's CEO) adds governance significance but does not change the core financial event classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-29
Item 3.02
VistaOne, L.P. sold approximately $24.2 million in unregistered limited partnership units across multiple classes (B, I, R, and S) as of September 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions. This private placement represents a dilutive issuance of equity securities to raise capital.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-29
Item 8.01
The Board of Directors has authorized a distribution to stockholders of record as of September 30, 2026, with specific per-share amounts disclosed for each class of common stock (ranging from $0.0163 to $0.0260 net per share). The distributions are payable in cash on or about October 19, 2026. This is a routine but material dividend distribution typical of a real estate investment trust (REIT).
View raw filing on EDGAR →